Antiviral

Ganoderic acid Z
Catalog No: CFN90295

The binding affinities of ganoderic acid DM and ganoderic acid Z (ΔGbind, −16.83 and−10.99 kcal mol−1) are comparable to that of current commercial drug oseltamivir (−23.62 kcal mol−1);Ganoderic acid DM is a potential source of anti-influenza ingredient, with novel binding pattern and advantage over oseltamivir, it has steric hindrance on the 150 cavity of N1 protein, and exerts activities across the H274Y and N294S mutations, is the attractive candidates of novel neuraminidase (NA) inhibitors.Ganoderic acid zeta has cytotoxicity in vitro against Meth-A and LLC cell lines.
Ganolucidic acid A
Catalog No: CFN90299

Ganolucidic acid A exhibits cytotoxicity, has inhibitory activities against human HeLa cervical cancer cell lines. It shows significant anti-human immunodeficiency virus (anti-HIV)-1 protease activity with IC50 values of 20-90 microM.
Ganoderone A
Catalog No: CFN90303

Ganoderone A exhibits potent inhibitory activity against herpes simplex virus. Ganoderone A exhibits strong inhibitory activities against Vero cells (IC50 is 0.3 ug/mL); it also has inhibition against cancer cell lines K562, SW620, and HL60, the 50% inhibiting concentration( IC50) are 9. 61, 22. 38, 7. 14 mg/L, respectively.
Artesunate
Catalog No: CFN90313

Artesunate is a part of the artemisinin group of agents with an IC50 of < 5 μM for small cell lung carcinoma cell line H69. It is a potential inhibitor of STAT-3 and exhibits selective cytotoxicity of cancer cells over normal cells in vitro; A potent inhibitor of EXP1.Artesunate has anti-inflammatory activity, can prevent neuroinflammation in BV2 microglia by interfering with NF-κB and p38 MAPK signalling.
Daphnoretin
Catalog No: CFN90329

Daphnoretin has strong antiviral activity, mainly on the later phase of the replication cycle. Daphnoretin has anticancer effects on leukemia, osteosarcoma and uterine cervix cancer cells, might through promoting apoptosis in a mitochondria-mediated way; it causes death of HOS cells by blocking cells successively in G2/M phases and activating the caspase-3 pathway.